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Background: Newborn screening (NBS) for cystic ﬁbrosis (CF) is a well-established public health strategy with international standards. The aim of
this study was to provide an update on NBS for CF in Europe and assess performance against the standards.
Methods: Questionnaires were sent to key workers in each European country.
Results: In 2016, there were 17 national programmes, 4 countries with regional programmes and 25 countries not screening in Europe. All national
programmes employed different protocols, with IRT-DNA the most common strategy. Five countries were not using DNA analysis. In addition,
the processing and structure of programmes varied considerably. Most programmes were achieving the ECFS standards with respect to timeliness,
but were less successful with respect to sensitivity and speciﬁcity.
Conclusions: There has been a steady increase in national CF NBS programmes across Europe with variable strategies and outcomes that reﬂect
the different approaches.
© 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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[1,2]. Increasingly, cystic fibrosis (CF) has become a core
component of these programmes. The rationale for NBS for
CF is well established and there is a robust evidence base to
support this strategy, however the challenges of this public
health initiative are well documented [3].
In 2004, the European CF Society (ECFS) established the
Neonatal Screening Working Group (NSWG) to track currentll rights reserved.
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consensus on issues arising in NBS. The first survey of the NSWG
was performed in 2004/2005 and identified a wide variety of CF
NBS programmes across Europe [4]. Of 26 programmes reported
in this publication, two were nationally co-ordinated (France and
Austria). In 2008, the NSWG published guidelines for CF NBS
and recognised the wide variance in protocols. They suggested
that given the geographic, ethnic, and health economic variations
between countries, complete harmonisation of protocols was not
appropriate, and every country had to evaluate and optimise their
approach to CFNBS in light of the health structure and population
screened [5].
In this study, we aim to provide 1) an update on CF NBS
programmes in Europe, 2) describe and discuss differences
between protocols, 3) identify barriers to establishing national
NBS programmes, and (4) compare the performance with the
recently published ECFS Standards of Care Best Practice
Guideline [6].
2. Methods
An important early task of the ECFS NSWG was to identify a
key worker in each country to provide information and act as a
local co-ordinator. This was achieved and enabled complete
coverage for the purpose of this exercise. The Core Committee of
the NSWG developed three distinct questionnaires; for countries
with national NBS programmes, regional NBS programmes, and
without NBS (Appendix). The questionnaire for the national
programmes was divided into 3 sections: (A) questions about the
screening protocol, (B) the performance of the protocol in the year
2014, and (C) the structure of NBS in the country. The first section
(A) included questions regarding the screening protocol with
description of the specific algorithm, proportion of the screened
population, sample collection (collection day), details of immune-
reactive trypsinogen (IRT) measurement, second tier used
including details of DNA analysis and/or pancreatitis-associated
protein (PAP), procedure for one mutation and safety net strategy.
The second section (B) included questions about the performance
of the protocol in the year 2014 (if available), including
the number of population screened, percentage above cut-off,
percentage of referrals for clinical assessment (sweat test), CF
diagnosis, inconclusive diagnosis, carrier detection, safety net,
average and median age for diagnosis, first appointment in a CF
centre, and number of false negatives and false positives. The third
section (C) included questions regarding the processing of results
including number of NBS laboratories in the country and details of
informed consent. The questionnaires were sent to the key worker
in each country in summer 2015. In some cases, they were not able
to complete the survey and were encouraged to forward the survey
to an appropriate colleague.
2.1. Data analysis
Performance of national programmes was assessed through
data obtained from the 2014 survey and subsequent follow-up
questionnaires to determine sensitivity by accurately reporting false
negative cases. Data from our 2016 survey were also included toPlease cite this article as: Barben J, et al, The expansion and performance of national n
http://dx.doi.org/10.1016/j.jcf.2016.12.012provide a more accurate assessment of practice in 2016, but not an
assessment of performance of those programmes.
The data were presented graphically. Positive predictive value
(PPV) was calculated as the number of true positive cases as a
proportion of all positive NBS results (presented as a percentage).
A positive NBS result was defined as an infant referred for clinical
and diagnostic assessment (sweat testing). We also collected data
about children screened positive for CF but their further clinical
and diagnostic assessment was inconclusive, and these children
were labelled as having an “inconclusive” diagnosis [7]. These
infants are designated as CF Screen Positive, Inconclusive
Diagnosis (CFSPID) in Europe [8]. We have included PPV
calculations with and without CFSPID infants.
Programmes were asked to report the number of affected but
not detected infants (false negatives) born in the year 2014. These
numbers were used to calculate the sensitivity of the protocol in
that year (the number of infants diagnosed with CF as a proportion
of all infants with CF born in 2014). Infants who presented
clinically (meconium ileus) but had a false negative NBS result
were not included in the sensitivity calculation as this presentation
does not delay diagnosis. We re-approached the 13 national
programmes in 2016 to enquire if any additional false negative
NBS results had been reported from 2014.3. Results
3.1. Description of the current status of NBS for CF across
Europe
A total of 31 countries provided data for 2014–2015 (16 returns
from national programmes, 4 from regional programmes and 11
from countries not screening). Fifteen countries did not provide a
full data reply, but confirmed that the situation had not changed (no
plans for NBS). Overall, this represents a considerable increase in
NBS programmes over a sixteen-year period, in particular national
programmes (Fig. 1). In 2007, the Working Group reported two
national programmes in Austria and France, although programmes
in Northern Ireland and Wales described as regional at that time
should now be considered national, as those countries have become
devolved authorities within the UK. At end of 2015, there were 17
national programmes in Europe, including the most recent,
Denmark (2015 data were not available for this country). Four
countries (Spain, Italy, Germany and Serbia) report regional
programmes. In Spain, there is complete coverage of the
population, but each region uses a distinct NBS protocol. Germany
has announced to start the national programme in September 2016.
Twenty-five countries have no current programme. Ten were
considering and planning for NBS programmes for CF. The most
frequently reported barrier to implementation was a lack of
financial support (4/11 countries). Other barriers included ethical
concerns, a preference for antenatal screening and methodological
arguments. In 2016, NBS for CF is undertaken in 21 countries in
Europe. For the 13 national programmes that provided complete
2014 datasets, this corresponds to 2.7 million screened babies per
year, compared to 1.6 million who were being screened annually
ten years ago [4]. Bearing in mind that 2014 data do not includeewborn screening programmes for cystic ﬁbrosis in Europe, J Cyst Fibros (2016),
Fig. 1. The status of NBS for CF in Europe in 2000, 2006 and 2016. National programmes are coloured dark green and regional programmes, light green. Countries
considering or planning NBS for CF are coloured orange and those with no plans, white.
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the time period.
3.2. Structure of national NBS protocols in Europe
There continues to be considerable variability in structure of
NBS programmes. The sixteen programmes that provided data on
structure all report a distinct algorithm (Table 1). All programmes
use measurement of IRT as the starting point (IRT-1). This
measurement is undertaken on a dried bloodspot sample (DBS)
taken in the first week of life (median day 3, ranging from days 2
to 8). Ten programmes report a fixed cut-off for IRT-1 ranging
from 60 to 90 ng/ml (median 65). Six programmes report a
floating cut-off to achieve a set percentage of samples sent for the
next level of testing (ranging 99.0th to 99.5th centile). Nine
programmes report exclusively using the Auto Delfia™ technol-
ogy for IRT measurement.
Themain factor contributing to the variability of programmes is
the approach taken to second tier testing. In four programmes, a
second sample is obtained at 14–21 days of age for a second IRT
measurement (IRT-2). In these IRT-IRT programmes, a persis-
tently raised IRT-2 value represents a positive NBS result and
infants are referred for diagnostic assessment. Two programmes
measure pancreatitis associated protein (PAP) on the initial DBS in
combination with the IRT-1 result to establish the need for further
testing. In one programme this is combined with subsequent DNA
analysis, but in the other a combination of raised IRT and PAP
values constitutes a positive NBS result. Most programmes (n, 10)
report using a DNA panel as the second tier test. The initial panel
size ranges from 4 to 644 mutations. Four programmes report
undertaking further IRT testing at day 21 (IRT-2) for infants withPlease cite this article as: Barben J, et al, The expansion and performance of national n
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IRT-2 value are reported as carriers with a low likelihood of CF. In
three programmes, extended gene sequencing (EGS) is undertaken
on samples in which one mutation has been recognised on the
initial panel. This provides opportunity for increased specificity if
only mutations that are recognised as CF causing are reported as
positive NBS results.
Ten countries employ a strategy which is called a “safety net”
(also known as failsafe or ultra-high IRT). For this strategy, infants
with a high IRT but no mutation recognised are referred for further
testing. In most programmes, this involves a referral for sweat
testing. In four programmes a repeat DBS is taken at day 21 and
the infant referred only if this is raised. In France, in the absence of
parental written consent for DNA analysis, the infant screened
positive is referred for a second IRT at day 21.
3.3. Managing the interface with the family
Written informed consent is mandatory in six (38%) countries
(Supplemental Table 1). In most countries the consent (oral or
written) is obtained by a midwife or community nurse. In four
countries, consent is obtained by a doctor. The DBS is obtained in
the hospital (8 countries) or family home [6], by a nurse or
midwife. In one country, the sample is taken in a GP surgery
(office) by a Primary Care Physician and in another at the local
health centre by a nurse.
A positive NBS result is most frequently reported by the CF
centre [9], and in most cases [10] this is by a phone call. The result
may be reported to the family by a CF Physician, a specialist CF
nurse, a community Nurse or a Family Doctor [3]. In two
countries, the NBS laboratories inform the family of the positiveewborn screening programmes for cystic ﬁbrosis in Europe, J Cyst Fibros (2016),
Table 1
The structure of 16 national NBS programmes for CF in Europe in 2015.
Northern Ireland Wales Austria France Scotland England Russia
Initiated (year) 1984 1996 1997 2002 2003 2007 2007
Protocol (2015) IRT
DNA
IRT
IRT
DNA
IRT
IRT
IRT
DNA
IRT
IRT
DNA
IRT
IRT
DNA
IRT
IRT
IRT
Day of IRT-sampling 5 5–8 3 3 5 5–8 4–5
IRT method Auto
Delfia
Auto
Delfia
Auto
Delfia
Auto
Delfia & Cisbio
& *GSP
Auto
Delfia
Auto
Delfia
Manuel Delfia
& Auto Delfia
IRT-1 fixed value in ng/ml Y
≥62
N Y
65
Y
65 (*60)
N N Y
70
IRT-1 floating centile (%) N Y
99.5%
N N Y
99.5%
Y
99.5%
N
PAP cut-off N N N N N N N
Initial DNA panel (no. of mutations) 29 8 NA 29 4 + 29 4 + 50 NA
Further testing if one mutation
identified
IRT-2
(day 21)
ST – ST IRT-2
(day 21)
IRT-2
(day 21)
–
Safety net threshold if tier 2 is negative IRT-1 ≥ 99.9% IRT-1 N 170 – IRT-1 N 100 IRT-1 N 99.9% IRT-1 N 99.9% –
Safety net strategy IRT-2
(day 21)
ST – IRT-2
(day 21)
IRT-2
(day 21)
IRT-2
(day 21)
–
4 J. Barben et al. / Journal of Cystic Fibrosis xx (2016) xxx–xxxresult. In three countries the result is given in the home and in three
countries the family are informed by letter, although in two this is
accompanied by a phone call. For subsequent genetic advice, this
was undertaken by Genetic Counsellors in 12 countries, with the
CF Physician in three and exclusively by the Physician in four.
3.4. Performance of national programmes
Thirteen national programmes provided performance data
for the year 2014 (Table 2). A wide variance in performance is
reported and there are consistent themes that can be recognised.
The incorporation of DNA analysis into a protocol results in an
improvement in positive predictive value (PPV), with fewer
false positive infants being referred for sweat testing. The
variance in PPV was considerable (range, 3 to 75%). Whilst the
use of extended gene sequencing is associated with improved
PPV, this is at the expense of increased recognition of infants with
an unclear diagnosis. For some countries, inclusion of CFSPID
infants results in a considerable improvement in PPV (for
example, in Poland from 23 to 42%). The ratio of infants with
CF compared to CFSPID ranged from 1.2:1 (Poland) to 32:1
(Ireland). Programmes incorporating DNA analysis were more
likely to recognise a higher proportion of infants with CFSPID
(Table 2). The median age of the infants diagnosed with CF when
they are first seen by a CF team was 26 days (range, 15–53).
There was no relationship between the algorithm employed and
age when seen at the CF centre (Table 2). Sensitivity ranged from
81 to 100%. In total, 12 infants with meconium ileus had IRT-1
values below the cut-off. These infants were excluded from the
sensitivity calculations.
When comparing the results to published ECFS standards,
only one programme was not achieving the minimum standard
for timeliness. However, four programmes did not achieve the
minimum 95% standard for sensitivity, and five programmes
had a PPV that was lower than the minimum standard of 30%
(Table 3).Please cite this article as: Barben J, et al, The expansion and performance of national n
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There has been a steady increase in NBS for CF across
Europe over the past ten years. Primarily this reflects the
emergence of national programmes. At the end of 2015, NBS
for CF is undertaken in 21 countries in Europe, 17 of them
within a national screening programme. Germany started their
national programme in September 2016 (Table 2), and Italy and
Spain continue to have extensive coverage of their populations
with regional programmes, with a wide variety of screening
protocols and outcomes. To compare protocol performance, we
restricted our analysis to national programmes with centralised
data collection, although it is appreciated that some regions in
Spain and Italy have considerable experience of NBS for CF
and sizeable populations to screen.
Despite expansion of NBS for CF across Europe, we
identified 25 European countries without NBS, including some
countries with well-established CF care programmes. Barriers
to implementation are predominately reported as political and
financial, as NBS for CF is now recognised as a valid public
health strategy for European populations [3].
The national programmes recorded in this survey report 16
different approaches to screening. This variance is a consistent
theme across the world [3]. The variability of approach reflects
a number of issues; 1) different health service models in
individual countries, 2) lack of a comprehensive bioethical tool
for assessing overall performance of CF NBS, 3) financial
implications and 4) barriers to change. The majority of
programmes [11] incorporate DNA analysis as a second tier
test, as per “Best Practice” recommendation, and five national
programmes report using biochemical tests only, either a repeat
IRT measurement at days 14–21 or measurement of PAP in
parallel to IRT-1. Ten programmes that use DNA analysis have
incorporated a “safety net” for infants with a very high IRT and
no mutations recognised. For most this involves a direct referral
for sweat testing, although in the UK and Switzerland, theewborn screening programmes for cystic ﬁbrosis in Europe, J Cyst Fibros (2016),
Table 1
Slovakia Czech Republic Poland Ireland Nether-lands Switzer-land Norway Turkey Portugal
2009 2009 2009 2011 2011 2011 2012 2015 2015
IRT
IRT
IRT
DNA
IRT
IRT
EGS
IRT
DNA
IRT
PAP
DNA
EGS
IRT
DNA
IRT
IRT
EGS
IRT
IRT
IRT
PAP
IRT
3–4 2–3 2 3–5 3–7 3–4 2 2 3–6
Neo IRT ILMA kit Auto
Delfia
IRT-neo-natal, IBL Auto
Delfia
Auto Delfia & GSP neonatal GSP neo-natal IRT GSP neo-natal IRT Manuel Delfia Auto
Delfia
Y
70
Y
65
N N Y
60/100
N Y
59.5
Y
90
Y
65/100
N N Y
99.4%
Y
99.0%
N Y
99.2%
N N N
N N N N Y
3.0/1.6
N N N Y
1.6/0.5
NA 50 644 38 35 18 92 NA NA
– ST EGS ST EGS ST EGS – –
– IRT-1 N 200 – – IRT-1 N 100 IRT-1 N 60 IRT-1 N 400 – IRT-1 N 150
– ST – – EGS IRT-2
(day 21)
ST – ST
5J. Barben et al. / Journal of Cystic Fibrosis xx (2016) xxx–xxxprogrammes undertake a second IRT measurement on a day 21
sample and only refer if that value is raised. Three programmes
(Poland, Netherlands and Norway) are using extended gene
sequencing for samples in which one mutation is recognised on
the initial panel.
The direct impact of NBS for CF on a family is considerable
and it is clear from the responses to this survey that there is
significant variability in how different programmes interact withTable 2
The performance of 13 national NBS programmes for CF in 2014.
Northern
Ireland
Wales Austria France Scotland Englan
Population (millions) 1.8 3.1 8.2 66.3 5.3 54.3
Birth per year 24,000 34,000 77,000 828,000 56,000 666,00
Number of babies with
IRT-1 N cut off
120
(0.50%)
170
(0.53%)
500
(0.60%)
3141
(0.39%)
405
(0.72%)
3842
(0.57%
Number of babies with
positive NBS result
(referred for sweat test)
16 27 130 409 24 255
CF diagnosis 4 9 25 139 18 157
CFSPID 0 0 1 17 NA 15
Carriers 15 18 NA 190 17 139
PPV
CF diagnosis only 25% 30% 20% 34% 75% 67%
CF & CFSPID 25% 30% 19% 38% 75% 73%
Ratio CF:CFSPID 0 0 25:1 8:1 NA 10.5:1
First seen in CF centre
(days, median)
CF diagnosis 22 21 30 34 24 22
CFSPID – – 30 54 38 22
Safety net
Investigations 10 3 - 559 29 321
CF diagnosis 0 0 7 0 6
False negatives
Without MI 0 1 1 8 0 3
Including MI 1 3 2 11 1 4
Sensitivity (without MI) 100% 90% 96% 95% 100% 98%
Abbreviations: IRT, immune-reactive trypsinogen; NBS, newborn screening; CFSP
MI, meconium ileus.
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http://dx.doi.org/10.1016/j.jcf.2016.12.012parent/carers. Informed consent is stated as a principle for all
programmes, orally in ten programmes and as written consent for
six. Consent is most frequently obtained by a midwife or
community nurse, although in some countries it is the responsi-
bility of a doctor. Processing a positive result is again an area of
variability, but there are some common themes, with most
reporting that the result is processed by the CF centre using a
phone call to make the first contact. In most cases the programmesd Slovakia Czech
Republic
Poland Ireland Nether-lands Switzer-land Norway
5.4 10.5 38.5 4.6 16.8 8.2 5.2
0 55,000 110,000 375,000 68,000 175′,000 86,000 60,000
)
848
(1.54%)
942
(0.90%)
2558
(0.60%)
670
(1%)
1004
(0.56%)
524
(0.61%)
491
(0.8%)
181 98 291 72 31 108 16
5 15 66 32 21 34 10
0 2 55 1 2 2 4
NA 80 170 40 6 46 58
3% 15% 23% 44% 68% 31% 63%
3% 17% 42% 46% 74% 33% 88%
0 7.5:1 1.2:1 32:1 10:1 17:1 2.5:1
15 31 53 23 25 18 26
– 85 55 23 25 25 29
- 40 - - 79 209 2
0 1 1 0
0 1 0 0 5 1 3
0 2 0 1 5 2 0
100% 94% 100% 100% 81% 97% 91%
ID, CF screen positive, inconclusive diagnosis; PPV, positive predictive value;
ewborn screening programmes for cystic ﬁbrosis in Europe, J Cyst Fibros (2016),
Table 3
A comparison of the performance of 13 national programmes with ECFS standards.
Standards of ECFS Care Guidelines (abbreviated) Number of countries (%)
achieving standards
Range of performance
1.3. The number of requests for repeat dried blood samples should be less than 0.5% Not available Not available
1.4. Positive predictive value (PPV) above 30% 8 (62%) 3–75%
1.5. Sensitivity above 95% 9 (69%) 81–100%
1.6. The sweat test should be analysed immediately and reported on the same day. Not available Not available
1.7. Infants with a confirmed diagnosis after NBS should be seen by the CF specialist team by
35 days (no later than 58 days after birth)
12 (92%) 15–53 days
6 J. Barben et al. / Journal of Cystic Fibrosis xx (2016) xxx–xxxreport referral to a genetic counsellor if required, but in four
programmes this information is provided by CF physicians.
With respect to the performance of the reported programmes, it
can be seen that the majority are achieving acceptable sensitivity.
The ECFS Standards of Care suggest that a sensitivity of 95% is a
minimum requirement, however four programmes reported results
that did not achieve this standard (Table 3). Some caution must be
exercised as false negative (affected but not detected) results are
challenging to collect, requiring reliable data collection systems.
Also, some of these children born in 2014 may not have
been recognised and diagnosed yet, although programmes were
approached for these data again in 2016. A standardised approach
for collecting false negative data would be of benefit for projects
comparing performance across countries. It is well recognised that
infants with meconium ileus regularly have IRT-1 values below
the cut-off and disproportionately contribute to false negative
datasets. In practical terms, these infants do not impact on
performance as the CF diagnosis is made clinically in the first
weeks of life. We have included sensitivity calculations without
meconium ileus cases, as per the ECFS standards.
With respect to standards for timeliness; that an infant
should be seen by the CF team within five weeks, only one
programme was routinely failing to achieve this standard
(Table 3). Despite this, programmes should not be complacent
and should continue to strive to minimise systematic delays in
their programmes. Programmes that are regularly reviewing
infants after four weeks should critically assess their perfor-
mance even though they are within current ECFS standards.
Programmes are performing less well with respect to PPV, with
only 62% achieving the PPV standard of 30%. For families this
equates to an acutely stressful time, as the false positive NBS
result is confirmed by sweat testing [9]. Overall protocols that
include DNA testing had higher PPV than biochemical protocols;
however this was not a completely consistent result, with some
IRT-DNA programmes not achieving the standard. Although
additional infants with CF were identified through various safety
net strategies, this was at the expense of a negative impact on PPV.
The data from this survey highlight the complexity of NBS for
CF and the relationship between different components of
algorithms and performance. Often a strategy that will improve
one aspect of performance will have a negative impact on
another, for example using more extensive DNA testing may
improve specificity but at the expense of increased carrier
recognition and the recognition of infants with CFSPID. There
are not sufficient data available to confidently assess the impact of
a CFSPID designation on families, but the general consensus isPlease cite this article as: Barben J, et al, The expansion and performance of national n
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As the initial data collection was undertaken in 2014 before a
clear definition of CFSPID was available, programmes have been
approached again to reassess their CFSPID numbers. Although
this resulted in minimal change to the initial data presented, it
would have been preferable for these infants to be designated in a
more prospective manner, raising the possibility that CFSPID
numbers were underestimated by this survey. Another outcome
from CF NBS that generates debate is the recognition of carriers,
with some arguing that this is beneficial to parents and even the
individual [11]. Again there are not sufficient data to confidently
assess the impact of carrier status on an individual or their family,
but the consensus is that carrier recognition should be minimised
in a public health screening programme [12]. Health services are
under pressure to consider increasingly complex DNA based
protocols for NBS for CF. It may be that this approach ultimately
leads to improved PPV and timeliness, however at present our
data suggest this may be at the expense of increased carrier and
CFSPID recognition. Policymakers need to carefully consider the
impact of such strategies on their population.
The expansion of NBS for CF across Europe has been a
success story, with most programmes performing adequately
with respect to international standards. This survey highlights
the challenges and the need for continued quality improvement
exercises. Programmes need to reflect critically on their
performance and embed data collection systems to evaluate
their outcomes prospectively. Large datasets are required to
confidently assess the performance of a NBS programme on a
specific population. Programmes should avoid altering cut-offs
and other aspects, for example the safety net, unless the impact is
carefully considered over time on a large dataset, but should also
be willing to embrace change if that will improve performance.
The main barrier to implementation is political inertia and CF
advocacy groups have been critical in overcoming this hurdle.
There is no longer a valid scientific rationale for not screening a
European population, although the results of this study highlight
the importance of careful protocol selection with respect to
achieving ECFS standards and minimising negative impact on
the population screened.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2016.12.012.Conﬂict of interest
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